Bulletin
Investor Alert

New York Markets Open in:

Beam Therapeutics Inc.

NAS: BEAM

GO
/marketstate/country/us

After Hours

/zigman2/quotes/216229751/composite

$

79.33

Change

-0.78 0.00%

Volume

Volume 4,583

Dec 8, 2021, 7:00 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/216229751/composite

Previous close

$ 78.66

$ 79.33

Change

+0.67 +0.85%

Day low

Day high

$74.09

$81.04

Open
Open: 78.97

52 week low

52 week high

$56.34

$138.52

Open

Market cap

$5.36B

Average volume

555,550

P/E ratio

N/A

Rev. per Employee

$132.60

EPS

-6.69

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/beam

MarketWatch News on BEAM

  1. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  2. Gene Therapy Is a Huge Opportunity. It Pays to be Patient.

    8:46 p.m. Nov. 5, 2021

    - Barron's Online

  3. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  4. Beam Therapeutics assumed at buy, up from hold, at Stifel Nicolaus

    6:55 a.m. Sept. 24, 2021

    - Tomi Kilgore

  5. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    8:21 a.m. June 30, 2021

    - Barron's Online

  6. How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks

    12:38 p.m. June 7, 2021

    - Barron's Online

  7. Cathie Wood's ARK Innovation Is Rebounding. She Bought the Dip.

    1:39 p.m. May 28, 2021

    - Barron's Online

  8. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  9. Beam Therapeutics downgraded to neutral from overweight at J.P. Morgan

    7:18 a.m. Jan. 29, 2021

    - Tomi Kilgore

  10. Beam Therapeutics initiated at hold with $84 price target at Stifel

    10:15 a.m. Jan. 6, 2021

    - Tonya Garcia

  11. Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics

    12:24 p.m. Oct. 7, 2020

    - Barron's Online

  12. These Companies Are Seeking a Cure for Sickle Cell

    10:53 a.m. July 25, 2020

    - Barron's Online

  13. Beam Therapeutics started at overweight with $31 stock price target at J.P. Morgan

    8:56 a.m. March 2, 2020

    - Tomi Kilgore

  14. Beam Therapeutics started at outperform with $32 stock price target at Wedbush

    7:58 a.m. March 2, 2020

    - Tomi Kilgore

  15. Loading more headlines...
/news/nonmarketwatch/company/us/beam

Other News on BEAM

  1. Intellia and gene editing rivals rally from recent slump

    3:02 p.m. Dec. 7, 2021

    - Seeking Alpha

  2. Where Will ARKK ETF Be In 5 Years? Struggling To Stay Afloat

    10:00 a.m. Dec. 3, 2021

    - Seeking Alpha

  3. Got $1,000? Check Out These 3 Top Biotech Stocks

    6:15 a.m. Dec. 3, 2021

    - Motley Fool

  4. Nanotechnology ETF is launched by Direxion Shares

    4:05 p.m. Nov. 23, 2021

    - Seeking Alpha

  5. Cathie Wood's Buying Beam Therapeutics -- Should You?

    9:15 a.m. Nov. 9, 2021

    - Motley Fool

  6. 10-Q: BEAM THERAPEUTICS INC.

    8:34 a.m. Nov. 8, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  7. Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

    6:20 a.m. Nov. 4, 2021

    - Zacks.com

  8. Should You Invest in the SPDR S&P Biotech ETF (XBI)?

    6:20 a.m. Oct. 29, 2021

    - Zacks.com

  9. 2 Gene-Editing Stocks to Have on Your Radar Right Now

    9:01 a.m. Oct. 17, 2021

    - Motley Fool

  10. Loading more headlines...
/news/pressrelease/company/us/beam

Press Releases on BEAM

  1. Loading more headlines...

Rates »

Trending Tickers
  • /zigman2/quotes/201786389/composite USA+0.11%
  • /zigman2/quotes/205971581/composite VIXM+1.50%
  • /zigman2/quotes/204412041/composite KMX+0.98%
  • /zigman2/quotes/205782082/composite IT-0.70%
  • /zigman2/quotes/200387963/composite LINK+1.77%
X
Powered by StockTwits
Link to MarketWatch's Slice.